Sangamo Therapeutics (SGMO) Cash from Operations (2016 - 2025)
Historic Cash from Operations for Sangamo Therapeutics (SGMO) over the last 17 years, with Q3 2025 value amounting to -$28.5 million.
- Sangamo Therapeutics' Cash from Operations fell 34235.05% to -$28.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$76.2 million, marking a year-over-year increase of 3338.7%. This contributed to the annual value of -$67.1 million for FY2024, which is 7013.95% up from last year.
- Latest data reveals that Sangamo Therapeutics reported Cash from Operations of -$28.5 million as of Q3 2025, which was down 34235.05% from -$18.2 million recorded in Q2 2025.
- In the past 5 years, Sangamo Therapeutics' Cash from Operations ranged from a high of $11.8 million in Q3 2024 and a low of -$68.6 million during Q1 2021
- For the 5-year period, Sangamo Therapeutics' Cash from Operations averaged around -$43.2 million, with its median value being -$52.6 million (2021).
- In the last 5 years, Sangamo Therapeutics' Cash from Operations crashed by 112733.41% in 2021 and then soared by 12486.41% in 2024.
- Quarter analysis of 5 years shows Sangamo Therapeutics' Cash from Operations stood at -$52.7 million in 2021, then fell by 8.22% to -$57.0 million in 2022, then increased by 11.41% to -$50.5 million in 2023, then surged by 93.37% to -$3.4 million in 2024, then tumbled by 750.43% to -$28.5 million in 2025.
- Its Cash from Operations stands at -$28.5 million for Q3 2025, versus -$18.2 million for Q2 2025 and -$26.1 million for Q1 2025.